Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chronic Lymphocytic Leukemia
95%
COVID-19
24%
Overall Survival
21%
Israeli
20%
Chronic Lymphocytic Leukemia Cells
17%
European Research
16%
Rituximab
15%
Cyclophosphamide
14%
Israel
13%
Working Diagnosis
12%
Fludarabine
12%
Chimeric Antigen Receptor T Cells (CAR-T)
10%
Non-Hodgkin Lymphoma
10%
Hematological Malignancies
10%
Diffuse Large B-cell Lymphoma (DLBCL)
10%
Positron Emission Tomography/computed Tomography (PET/CT)
10%
Obinutuzumab
9%
Leukemia Patients
8%
Richter Transformation
8%
B-cell Receptor Signaling
8%
Acalabrutinib
8%
Chemoimmunotherapy
7%
Leukemia
7%
Elderly Patients
7%
Clinical Trials
7%
Progression-free Survival
7%
Ibrutinib
7%
Chlorambucil
6%
Hodgkin Disease
6%
C-reactive Protein
6%
Lymphoma
6%
Prognostic Significance
6%
CD74
6%
Frontline Therapy
5%
Lymphoma Patients
5%
Microenvironment
5%
Venetoclax
5%
BNT162b2
5%
Lymphoproliferative Disorders
5%
CD84
5%
Hodgkin
5%
Azacitidine
5%
B-cell non-Hodgkin Lymphoma (B-NHL)
5%
Hairy Cell Leukemia
5%
CT Pattern
5%
Venous Thrombosis
5%
18F-fluorocholine PET/CT
5%
Relapsed/refractory
5%
Group Experiences
5%
Inpatient Treatment
5%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
100%
Overall Survival
28%
Diseases
23%
Diffuse Large B-Cell Lymphoma
22%
Rituximab
21%
COVID-19
18%
Progression Free Survival
15%
Retrospective Study
13%
Hodgkin's Lymphoma
11%
Positron Emission Tomography-Computed Tomography
11%
Obinutuzumab
11%
Richter's Transformation
10%
Chronic Lymphocytic Leukemia
10%
Chimeric Antigen Receptor T-Cell
10%
Cyclophosphamide
9%
Myelodysplastic Syndrome
9%
Elderly Patient
9%
Chlorambucil
9%
Leukemia Cell
9%
Non-Hodgkin Lymphoma
8%
B Lymphocyte Receptor
8%
Acalabrutinib
8%
Azacitidine
8%
Chemoimmunotherapy
8%
Chemotherapy
7%
Infection
6%
Fluorodeoxyglucose
6%
Ibrutinib
6%
Fludarabine
6%
Fluorine-18
6%
Venetoclax
6%
Cohort Analysis
5%
C Reactive Protein
5%
Phlebothrombosis
5%
Patient with Non-Hodgkins Lymphoma
5%
Polyethylene Terephthalate
5%
Prognostic Factor
5%
Clinical Trial
5%
Thrombocytopenia
5%
Fluorodeoxyglucose F 18
5%
Follicular Lymphoma
5%
MALT Lymphoma
5%
Arm
5%
Tomography
5%
Immunology and Microbiology
B Cell
31%
COVID-19
27%
Leukemia Cell
24%
Overall Survival
16%
CD19
13%
Infectious Disease
12%
Infection
12%
B-Cell Receptor
11%
CD84
10%
Chimeric Antigen Receptor T-Cell
10%
Myeloid
9%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
C-Reactive Protein
7%
Humoral Immunity
7%
Booster Dose
7%
Progression Free Survival
6%
Immunoglobulin M
6%
Leukocyte Count
6%
Seroconversion
6%
CD74
6%
Lymphocyte
5%
Ribonucleic Acid
5%